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cantly higher TC, LDL cholesterol, apo B, and LP-B levelsApolipoprotein B-containing lipoproteins in renal failure: The
than HTG-HD patients. The LP-Bc levels were significantlyrelation to mode of dialysis.
increased in HTG-HD and HTG-CAPD patients comparedBackground. The aim of this study was to establish whether
with controls, but the slightly higher levels in the CAPD pa-there is a differential effect of mode of dialysis, hemodialysis
tients did not differ significantly from the HD group.(HD), or continuous ambulatory peritoneal dialysis (CAPD)
on the dyslipidemia of renal failure. Conclusion. CAPD and HD patients have a lipoprotein pro-
Methods. The lipoprotein profile was determined in 61 non- file characteristic of renal failure. Patients on long-term CAPD
diabetic patients on chronic HD (N 5 30) and CAPD treatment have higher levels of cholesterol-rich apo B-containing lipopro-
(N 5 31), and in a control group of 27 healthy subjects. The teins unrelated to TG levels. Many patients on CAPD also
analysis included the measurement of individual apolipoprotein have a substantial elevation of the plasma concentrations of
(apo) A- and apo B-containing lipoproteins (LPs) separated by TG-rich LPs. The clinical significance of increased levels of
sequential immunoaffinity chromatography. Apo A-containing potentially atherogenic LP-B during CAPD remains to be in-
lipoproteins include lipoprotein A-I with apo A-I and lipopro- vestigated.
tein A-I:A-II with apo A-I and apo A-II as the main protein
constituents, whereas apo B-containing lipoproteins comprise
simple cholesterol-rich lipoprotein B (LP-B), with apo B as
Renal insufficiency is associated with abnormal con-the only protein moiety and complex triglyceride (TG)-rich
lipoprotein B complex (LP-Bc) particles with apo B, apo A-II, centrations and composition of plasma lipoproteins [1].
apo C, and/or apo E as the protein constituents. This dyslipidemia can already be detected at the early
Results. CAPD patients had significantly higher concentra- asymptomatic stages of renal insufficiency and becomestions of total cholesterol (6.8 vs. 5.1 mmol/liter), low-density
more pronounced as renal failure advances and contin-lipoprotein (LDL) cholesterol (4.6 vs. 3.2 mmol/liter), TG (2.3
ues to affect patients on maintenance dialysis therapy.vs. 1.5 mmol/liter), apo B (155.3 vs. 105.7 mg/dl), LP-B (136.0
vs. 91.9 mg/dl), and LP-Bc (19.3 vs. 13.8 mg/dl) than HD pa- Hemodialysis (HD) and continuous ambulatory perito-
tients. Both HD and CAPD patients had significantly higher neal dialysis (CAPD) can both provide adequate relief
TG, VLDL cholesterol, apo C-III, and apo E and significantly of uremic symptoms, however, the two modes of dialysislower high-density lipoprotein cholesterol, apo A-II, and lipo-
seem to differ in their effect on the uremic dyslipidemiaprotein A-I:A-II levels than control subjects. The distribution
[1, 2]. Previous studies have indicated that long-termof apo C-III in high-density lipoprotein and VLDL-LDL was
altered in CAPD patients in comparison with control subjects. treatment with CAPD may further aggravate some of
This suggests that the removal of TG-rich lipoproteins is less the lipoprotein abnormalities [3–14].
efficient in patients on CAPD. Normotriglyceridemic (NTG;
Renal dyslipidemia is characterized to a greater ex-TG # 1.7 mmol/liter, 150 mg/dl) CAPD patients had signifi-
tent by abnormal apolipoprotein rather than lipid pro-cantly higher levels of TC, LDL cholesterol, apo B, and LP-B
than NTG-HD patients. There was little difference in the LP- file, including decreased levels of apolipoprotein (apo)
Bc levels between NTG-CAPD, NTG-HD, and controls. Simi- A-containing lipoproteins and increased levels of apo
larly, hypertriglyceridemic (HTG) CAPD patients had signifi- B-containing lipoproteins [1]. Apo A-containing lipopro-
teins consist of two major lipoprotein families: (1) lipo-
protein A-I, with apo A-I as the characteristic proteinKey words: chronic renal failure, CAPD, hemodialysis, lipids, apolipo-
proteins, dyslipidemia. constituent, and (2) lipoprotein A-I:A-II, which contains
apo A-I and apo A-II as the main protein components
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[15]. The simple cholesterol-rich lipoprotein B (LP-B)and in revised form November 12, 1998
Accepted for publication November 12, 1998 and the complex triglyceride (TG)-rich lipoproteins, re-
ferred to as LP-B complex (LP-Bc), are the two major 1999 by the International Society of Nephrology
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Table 1. Clinical characteristics of patients on CAPD, patients on The HD patients were treated with conventional HD
hemodialysis (HD) and in healthy control subjects
with bicarbonate-containing dialysis fluid and non-Cupro-
Age Sex BMI Time on dialysis phane low-flux dialysis membranes. Most patients were
N years m/f kg/m2 months treated three times weekly for four to five hours using
CAPD 31 60.0 (33–85) 20/11 24.2 (3.2) 16.2 (13.5) low molecular weight heparin for anticoagulation. They
HD 30 63.4 (42–81) 17/13 23.7 (4.6) 36.6 (30.9)
had a mean Kt/V of 1.2 6 0.2.Control 27 51.1 (35–75) 18/9 NR NA
The CAPD patients were treated with glucose-con-Abbreviations are: BMI, body mass index; m/f, male/female; NR, not recorded;
NA, not applicable. taining peritoneal dialysis fluids with a mean exchange
volume of 10.0 6 3.8 liter/day and a mean total weekly
creatinine clearance of 74.2 6 17.4 liter.
None of the patients were treated with any lipid-low-groups of apo B-containing lipoproteins [15]. The LP-B
ering drugs or corresponding dietary counseling. No pa-particles contain apo B as the only protein constitu-
tient on immunosuppressive therapy or with an ongoingent and occur predominantly in the low-density lipopro-
intercurrent illness was included in the study. The patientstein (LDL) range. The LP-Bc particles contain varying
were recruited during a limited period of time, duringamounts of apo A-II, apo C, and/or apo E in addition
which no major changes in dialysis treatment or pre-to apo B as the protein constituents, and may be detected
scription medication were instituted. The patients wereas intact or partially delipidized lipoproteins in very low-
treated with phosphate binders, potassium-binding res-density lipoprotein (VLDL), intermediate-density lipo-
ins, vitamins, and supplementation with iron and erythro-protein (IDL), and LDL ranges.
poietin, as appropriate. Twenty-four (77%) of the CAPDThe purpose of this study was to determine the concen-
trations of apo A- and apo B-containing lipoproteins in patients and 20 (66%) of the HD patients were treated
patients with end-stage renal disease treated by CAPD with antihypertensive drugs. The treatment frequencies
or HD. in the CAPD patient of specific drugs were 52% on
b-adrenoceptor blockers, 19% on calcium-antagonists,
16% on angiotensin-converting enzyme inhibitors, andMETHODS
56% on loop diuretics. The corresponding frequencies
The study was conducted in accordance with the ethi- in the HD patients were 34%, 38%, 18%, and 41%,
cal principles described by the Declaration of Helsinki respectively.
and was approved by the Sahlgrenska University Hospi- The control subjects were recruited among healthy
tal Ethics Committee. Swedish subjects.
Patients and controls Analytical methods
Thirty-one patients on CAPD, 30 patients on HD, and Blood samples for lipid and lipoprotein determina-
27 healthy control subjects were studied. The patients tions were drawn via antecubital venipuncture after an
were all whites recruited from two dialysis centers in
overnight fast. In HD patients, blood was drawn prior
southern Sweden. Only nondiabetic patients with at least
to dialysis. The CAPD patients continued their dialysisa six-month duration of stable maintenance dialytic treat-
during sampling. Plasma samples were preserved usingment were included in the study. Clinical characteristics
ethylenediaminetetraacetic acid (EDTA; final concen-of the patients and the controls are presented in Table 1.
tration 1 mg/ml) and e-aminocaproic acid (1.3 mg/ml).The two patient groups had the same age and sex distri-
All samples were shipped in the fresh state by expressbution and did not differ in body mass index. They had
air freight to the Lipid and Lipoprotein Laboratory at theidentical distribution of the underlying renal disorders.
Oklahoma Medical Research Foundation for analysis.Twelve (40%) of the HD patients had chronic glomeru-
lonephritis. Six (20%) had interstitial nephritis. Three Lipids and apolipoproteins
(10%) had adult polycystic kidney disease. One (3%)
Total cholesterol (TC) and TG contents were deter-had amyloidosis, and five (17%) had nephrosclerosis as
mined by enzymatic methods as previously described [16].the underlying renal disease. In the remaining three
Concentrations of apo A-I, apo A-II, apo B, apo C-III,(10%) patients, the renal disorder could not be ade-
and apo E were measured by electroimmunoassays usingquately diagnosed. The corresponding frequencies in the
monospecific antisera as previously described [17–20]. TheCAPD patients were 13 (42%), six (19%), three (10%),
distribution of apo C-III polypeptides was determined byone (3%), five (16%), and three (10%). Although both
measuring apo C-III in heparin-Mn11 supernates (thatgroups had been on their respective mode of dialysis
is, in HDL) and precipitates (that is, in VLDL 1 LDL).for at least six months, the HD patients’ duration of
A lower ratio indicated less efficient catabolism and re-treatment was approximately twice as long as that of the
CAPD patient group. moval of TG-rich lipoproteins [21].
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Table 2. Plasma lipid concentrations, mean and standard deviation (in parentheses), in patients on CAPD, patients on hemodialysis (HD)
and in healthy control subjects
Cholesterol Triglycerides VLDL LDL HDL
mmol /liter
CAPD (N 5 31) 6.80c,f (1.52) 2.30b,f (1.24) 0.99a,f (0.43) 4.60c,f (1.21) 1.12d (0.32)
HD (N 5 30) 5.12 (1.37) 1.53f (0.95) 0.70f (0.43) 3.16 (1.24) 1.26d (0.41)
Control (N 5 27) 5.48 (1.03) 0.84 (0.39) 0.39 (0.18) 3.54 (0.95) 1.50 (0.44)
a P , 0.05, b P , 0.01, c P , 0.001 vs. HD
d P , 0.05, e P , 0.01, f P , 0.001 vs. Control
Table 3. Plasma lipid concentrations, mean and standard deviation (in parentheses), in patients on CAPD and in patients on
hemodialysis (HD) according to normo- (NTG) or hypertriglyceridemia (HTG)
Cholesterol Triglycerides VLDL LDL HDL
mmol /liter
Normotriglyceridemic patients
CAPD (N 5 10) 5.79a (1.29) 1.15 (0.34) 0.52 (0.15) 4.01a (1.05) 1.25 (0.35)
HD (N 5 20) 4.78 (1.20) 1.00 (0.33) 0.46 (0.15) 2.99 (1.25) 1.34 (0.41)
Hypertriglyceridemic patients
CAPD (N 5 21) 7.28a (1.40) 2.87 (1.12) 1.22 (0.32) 4.89b (1.20) 1.05 (0.29)
HD (N 5 10) 5.80 (1.51) 2.61 (0.89) 1.19 (0.40) 3.51 (1.19) 1.11 (0.37)
The cut-off level of HTG was a TG level above 1.7 mmol/liter.
a P , 0.05, b , 0.01 vs. HD
Lipoprotein particles RESULTS
Plasma lipidsLipoprotein A-I and lipoprotein A-I:A-II were isolated
by immunoaffinity chromatography as previously de- Both CAPD and HD patients had increased plasma
scribed [22]. The two major classes of apo B-containing TG concentrations in comparison to the controls. Hyper-
lipoprotein families, cholesterol-rich LP-B and TG-rich triglyceridemia was found in 68% (21 out of 31) of the
LP-Bc, were separated by immunoaffinity chromatogra- CAPD patients and in 33% (10 out of 30) of the HD
patients (Tables 2 and 3). Total and LDL cholesterolphy of whole plasma on an anti-apo C-III immunosorber
levels were elevated only in the CAPD patients. CAPD[23]. The retained and unretained fractions were then
patients had higher TC and LDL cholesterol levels thanseparately analyzed for apo B.
HD patients, regardless of the presence of hypertriglyc-
eridemia (Table 3). Both CAPD and HD patients hadStatistical methods
significantly elevated VLDL cholesterol, which was mostStandard statistics were used to illustrate the salient
pronounced in the CAPD patients. HDL cholesterol lev-features of the data. One-way analysis of variance was
els were characteristically reduced in both dialysis groupsused to determine significant differences among groups
(Table 2).
for plasma lipids, apolipoproteins, and lipoprotein parti-
cles. For variables that were significantly different by Plasma apolipoproteins
analysis of variance, Student’s t-test was used to compare Plasma concentrations of apo A-I and apo A-II were
means between the control group and each dialysis group lower in both the CAPD and HD patients than in con-
and between the two dialysis groups. Correlations be- trols, but did not differ between the two dialysis groups
tween lipoprotein variables have been analyzed using (Tables 4 and 5). The CAPD patients had higher concen-
Pearson’s coefficients for pair-wise comparison. P values trations of apo B than either the HD patients or controls.
of less than 0.05 were considered as statistically significant. Elevated apo B levels were observed in CAPD patients
The statistical comparisons were also performed in the in both NTG and HTG groups (Table 5). Apo C-III
two patient categories after separating them according to and apo E levels were elevated in both CAPD and HD
their TG levels into normotriglyceridemic (NTG) and patients. The elevation of apo C-III levels was more
hypertriglyceridemic (HTG) patients. The cut-off limit pronounced in CAPD patients, mainly because of a sig-
was a TG level of 1.7 mmol/liter. Data are expressed as nificant increase of apo C-III in VLDL and LDL, being
more than twice as high as in HD patients. This alsomeans with standard deviation unless otherwise stated.
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Table 4. Plasma apolipoprotein concentrations, mean and standard deviation (in parentheses), in patients on CAPD,
patients on hemodialysis (HD) and in healthy control subjects
Apo A-I Apo A-II Apo B Apo C-III Apo E
mg/100 ml
CAPD (N 5 31) 117.4a (21.0) 64.1a (16.3) 155.3a,b (38.8) 22.4a,c (7.7) 12.9a (3.5)
HD (N 5 30) 124.3d (27.2) 63.6a (16.5) 105.7 (34.8) 18.2a (4.8) 11.4a (2.9)
Control (N 5 27) 141.8 (27.4) 78.3 (13.6) 105.7 (25.7) 10.9 (2.5) 7.7 (2.0)
a P , 0.001 vs. Control, b P , 0.001 vs. HD
c P , 0.05 vs. HD, d P , 0.05 vs. Control
Table 5. Plasma apolipoprotein concentrations, mean and standard deviation (in parentheses), in patients on CAPD and in patients on
hemodialysis (HD) according to normo- (NTG) or hypertriglyceridemia (HTG)
Apo A-I Apo A-II Apo B Apo C-III Apo E
mg/100 ml
Normotriglyceridemic patients
CAPD (N 5 10) 118.8 (29.9) 64.4 (18.0) 123.4a (31.9) 15.6 (3.5) 10.2 (2.0)
HD (N 5 20) 125.5 (28.5) 62.7 (16.6) 95.0 (29.9) 16.6 (3.4) 10.7 (2.5)
Hypertriglyceridemic patients
CAPD (N 5 21) 116.8 (16.1) 63.9 (15.8) 170.5b (32.4) 25.6 (7.0) 14.2 (3.3)
HD (N 5 10) 121.9 (25.5) 65.5 (16.9) 127.1 (35.5) 21.2 (5.9) 12.8 (3.2)
The cut-off level of HTG was a TG level above 1.7 mmol/liter.
a P , 0.05, b P , 0.01 vs. HD
Table 6. Apo A- and apo B-containing lipoproteins, mean and in HD patients was not statistically significant. There was
standard deviation (in parentheses), in patients on CAPD, patients
no evidence for a “preferential” reduction in the levelson hemodialysis (HD) and in healthy control subjects
of either lipoprotein A-I or lipoprotein A-I:A-II.
Apo A-containing Apo B-containing
lipoproteins lipoproteins Apolipoprotein B-containing lipoproteins
LP-A-I LP-A-I:A-II LP-B LP-Bc
Levels of cholesterol-rich LP-B were increased by 40%
mg/100 ml in CAPD patients compared with HD patients and con-
CAPD (N 5 31) 31.7d (4.9) 85.8e (19.9) 136.0b,e (35.3) 19.3a,e (11.1) trols (Tables 6 and 7). There was a significant correlation
HD (N 5 30) 33.3 (8.0) 91.0c (22.0) 91.9 (29.3) 13.8 (7.9) between plasma concentrations of TC and LP-B in all ofControl (N 5 27) 36.4 (7.7) 105.4 (21.3) 94.4 (25.7) 11.3 (5.1)
the groups (CAPD, r 5 0.86; HD, r 5 0.91; controls, r 5
a P , 0.05, b P , 0.001 vs. HD
0.77, P , 0.001).c P , 0.05, d P , 0.01, e P , 0.001 vs. Control
The CAPD patients had an almost twice as high of a
plasma concentration of TG-rich LP-Bc compared with
controls. They also had higher LP-Bc levels than the HD
resulted in a markedly reduced ratio of apo C-III in patients, who had a marginally but nonsignificantly higher
HDL to apo C-III in VLDL and LDL in the CAPD level than the control subjects. Serum TGs also correlated
patients (0.6 6 0.5) than in both HD patients (2.1 6 1.5, with the levels of LP-Bc, but with lower correlation coeffi-
P , 0.001) and in controls (1.8 6 1.3, P , 0.001). A cients (CAPD, r 5 0.44, P , 0.05; HD, r 5 0.38, P ,
similar pattern was observed in both HTG and NTG 0.05; control, r 5 0.32, NS).
patients. These changes also resulted in an approximate
50% decrease in the apo A-I/apo C-III ratio when com-
DISCUSSIONpared with that of controls (13.4 6 3.1, P , 0.001), with
CAPD patients having a significantly lower ratio (5.8 6 To our knowledge, this is the first report on plasma
1.9) than the HD patients (7.3 6 2.5, P , 0.01). levels of discrete lipoprotein families separated by immu-
noaffinity chromatography in dialysis patients. Our find-
Apo A-containing lipoproteins ings confirm and extend previous observations that have
Levels of both lipoprotein A-I and lipoprotein A-I:A-II reported that hyperlipidemia is a common feature in
were significantly reduced in patients treated by CAPD CAPD patients with increased levels of both TC and TG
compared with control subjects ((Tables 6 and 7). A simi- [3–14, 24]. The alterations of the lipoprotein profile are
lar, but less pronounced, pattern was observed in the HD more marked in CAPD patients than in patients on HD.
The CAPD patients had significantly higher levels of cho-patients, although the reduction in lipoprotein A-I levels
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Table 7. Apo A- and apo B-containing lipoproteins, mean and standard deviation (in parentheses), in patients on CAPD and in patients
on hemodialysis (HD) according to normo- (NTG) or hypertriglyceridemia (HTG)
Apo A-containing Apo B-containing
lipoproteins lipoproteins
LP-A-I LP-A-I:A-II LP-B LP-Bc
mg/100 ml
Normotriglyceridemic patients
CAPD (N 5 10) 31.2 (6.1) 87.6 (25.1) 110.1a (26.7) 13.3 (7.5)
HD (N 5 20) 34.2 (18.5) 91.3 (23.3) 83.1 (24.3) 11.9 (7.7)
Hypertriglyceridemic patients
CAPD (N 5 21) 31.9 (4.3) 84.9 (13.9) 148.4b (32.5) 22.1 (11.5)
HD (N 5 10) 31.6 (6.9) 90.3 (20.2) 109.4 (31.8) 17.7 (22.1)
The cut-off level of HTG was a TG level above 1.7 mmol/liter.
a P , 0.05, b P , 0.01 vs. HD
lesterol-rich LP-B particles and slightly higher levels of dialysis [5]. If anything, Wheeler concluded in a recent
review that the changes in lipoprotein metabolism associ-intact or partially delipidized TG-rich LP-Bc particles.
Previous studies have indicated that, in general, the LP-B ated with CAPD appear to occur early during the course
of treatment to remain essentially stable during two toparticles are not markedly elevated in renal failure [1].
These findings indicate that the CAPD treatment may three years [13].
We have shown earlier that renal insufficiency is accom-contribute to a further increase in the cholesterol-rich
lipoproteins unrelated to TG levels. panied by characteristic changes in the lipoprotein profile
that are detectable from the asymptomatic stages of renalThe patients included in this study represent stable,
nondiabetic patients on chronic maintenance dialysis at- insufficiency throughout the course of renal failure and
dialysis [1, 26]. Characteristics of the renal dyslipidemiatending two larger out-patient dialysis centers in Sweden.
In order to avoid other metabolic influences than that of include increased concentrations of intact and partially
metabolized apo B-containing lipoproteins together withthe dialytic treatment modality and of uremia itself, pa-
tients with diabetic mellitus or lipid-lowering intervention a decrease of the apo A-containing lipoproteins [1]. This
characteristic pattern was also seen in these groups ofwere excluded from the study. The patients were ade-
quately dialyzed by current standards and were main- CAPD and HD patients, although the elevation of LP-Bc
levels was surprisingly modest in the HD group. Both pa-tained in a fair nutritional status as evidenced by the body
mass index values. Both the HD and the CAPD group tient categories showed the characteristic increase in the
levels of apo C-III and a reduced apo A-I/apo C-III ratio,of patients had similar plasma lipid profiles, respectively,
as previously have been reported in these two patient considered to be the hallmark of renal dyslipidemia [1].
Llopart et al observed that CAPD patients in compari-categories [3–14, 24]. There were only minor differences
in antihypertensive drug treatment between the study son with HD patients had characteristic abnormalities
of the TG-rich lipoproteins with significantly increasedgroups. Furthermore, the effects of b-adrenoceptor block-
ers and diuretics on the lipoprotein pattern have been levels of cholesterol- and TG-enriched VLDL and IDL
[27]. This can be explained by the marked elevation ofshown to be marginal during long-term treatment [25].
Hence, the antihypertensive therapy cannot explain the the complex apo B-containing lipoproteins LP-Bc parti-
cles. Thus, the patients on maintenance CAPD treatmentobserved differences in the lipoprotein profile in the
CAPD and HD patients. in this study exhibited marked changes in the concentra-
tions and composition of individual lipoprotein particles,The HD group had been treated with dialysis for an
average duration of approximately three years. This was which is in accordance with other observations in this
patient category [7, 8].considerably longer than the duration of dialysis in the
CAPD group, which was slightly over one year. However, The major underlying abnormality of lipid transport
in renal failure appears to be a reduced catabolism of theit is unlikely that this difference in dialysis duration could
explain the differences in lipoprotein profile between the apo B-containing lipoproteins [1]. The more pronounced
reduction of the apo C-III ratio in the CAPD patientstwo study groups [5]. The differences between HD and
CAPD patients were also not likely to be attributable to suggests that the removal of TG-rich lipoproteins may be
less efficient in these patients than in HD patients [21].the nutritional status of the two groups. The body mass
index was similar in both groups, and the HD patients This may be caused by a decreased activity of lipolytic
enzymes, notably lipoprotein lipase, with a possible linkwere generally well nourished. Sniderman et al showed
that in patients with long-term maintenance dialysis, varia- to alterations of insulin action in renal failure [1]. Com-
positional changes of the apo B-containing lipoproteins,tions in the duration of dialysis did not account for the
different lipid profile associated with these two modes of as reflected in their apolipoprotein compositions, may be
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another important contributing factor. Such alterations IDL and aortic atherosclerosis in dialysis patients [37].
may render the apo B-containing lipoproteins less suitable Recent studies have convincingly demonstrated that
as substrates for lipolysis [1]. The increased content of apo both the cholesterol-rich (LP-B) and the TG-rich apo
C-III could be one of the crucial abnormalities, the cause B-containing lipoproteins (LP-Bc) have atherogenic prop-
of which is still unexplained [1]. Apart from alterations erties and can play a role in the development of cardio-
in substrate characteristics, the abnormal lipoprotein vascular disease in nonrenal patients [15]. These results
composition may also result in a reduced cellular uptake could indicate that increased concentrations of choles-
of lipoproteins mediated by the LDL pathways. Apo E terol-rich LP-B in CAPD patients may constitute a fur-
is a ligand for this receptor-mediated uptake, whereas ther risk factor for atherosclerosis in addition to the
apo C-III may interfere with these processes. Hence, an exposure to the atherogenic TG-rich LP-Bc.
increased apo C-III/apo E ratio in renal dyslipidemia [1, Cardiovascular complications account for the majority
26] could contribute to reduced cellular uptake of apo of premature deaths during dialysis treatment [38, 39]. It
B-containing lipoproteins in patients with renal failure remains to be clarified whether patients on maintenance
As a consequence, an accumulation of both intact or par- CAPD treatment, with their cluster of metabolic and
tially delipidized TG-rich lipoproteins, that is, of LP-Bc hemostatic cardiovascular risk factors [24], also have a
particles, can be anticipated. It remains controversial more pronounced and accelerated development of pre-
whether the use of low molecular weight heparin for mature atherosclerosis than HD patients [8, 13, 14, 40–42].
anticoagulation purposes may have contributed to the Currently, such comparative studies have been impossi-
lower TG levels in the HD patients in the study [28, 29]. ble to conduct because of the unavoidable selection bias
However, these mechanisms cannot readily explain for the respective treatments in current clinical practice.
the marked increase in the levels of cholesterol-rich In conclusion, the results of this study show that main-
LP-B particles observed in CAPD patients. Metaboli- tenance CAPD treatment is associated with more pro-
cally, the CAPD patient population differs from HD or nounced alterations of the lipoprotein metabolism than
predialytic patients with renal insufficiency. First, these those observed during HD treatment. The reduced levels
patients have an increased lipoprotein substrate avail- of apo A-containing lipoproteins and increased levels of
ability through glucose uptake from the peritoneal dial- both cholesterol-rich and TG-rich apo B-containing lipo-
ysis fluid, which may contribute to an increased hepatic proteins indicate a clear atherogenic pattern. These find-
synthesis of apo B-containing lipoproteins [2, 13]. An ings may be of importance for selecting and monitoring
increase in body fat is frequently seen after long-term
the appropriate preventive measures for normalizing dys-
CAPD treatment, reflecting a high caloric intake [30].
lipidemia in these patients. Future studies on such measuresSecond, another underlying mechanism may be related
may include modifications of dialysis fluids for CAPD andto the loss of large molecular weight substances in the
targeted pharmacological lipid-lowering intervention.peritoneal dialysis fluid [1, 4, 13, 31]. It has been demon-
strated that the daily clearance of apo A-I is twofold to
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